Oxford Biomedica

Oxford Biomedica is a pioneer in gene and cell therapy, leading the industry in lentiviral vector and cell therapy research, development, and manufacturing. Gene therapy treats diseases by introducing therapeutic DNA into patients' cells. This can be done either in vivo or ex vivo, the latter encompassing the field of cell therapy, where genetically modified cells are reintroduced into the body. They produce seven gene and cell therapy products aimed at treating diseases that currently lack effective treatments, including ocular and central nervous system disorders. Their pipeline candidates have the potential to transform the treatment landscape. Their strategy is to advance their pipeline products to the next value inflection point while continuing to build OXB Solutions into a valuable revenue-generating manufacturing and development services business.